MedTrace Logo

Lenalidomide Plus Rituximab (R) in Non Follicular NHL

NCT01830478 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2013-04-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether lenalidomide in association with rituximab is effective in the treatment of patients with indolent non follicular NHL relapsed after \>=2, but less than 4 prior lines of (immuno)chemotherapy.

Conditions

  • Indolent Non Hodgkin Lymphoma

Interventions

DRUG

Lenalidomide

Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles

DRUG

Rituximab

Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles

Sponsors & Collaborators

  • Gruppo Italiano Studio Linfomi

    lead OTHER

Principal Investigators

  • Stefano Sacchi, MD · Gruppo Italiano Studi Linfomi

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-12-31
Completion
2014-10-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01830478 on ClinicalTrials.gov